GH Research (NASDAQ:GHRS) Now Covered by Analysts at Guggenheim

Guggenheim initiated coverage on shares of GH Research (NASDAQ:GHRS - Get Free Report) in a research note issued on Thursday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $32.00 price target on the stock. Guggenheim's price objective points to a potential upside of 181.94% from the company's previous close.

GHRS has been the subject of a number of other research reports. Stifel Nicolaus boosted their price objective on shares of GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of GH Research in a report on Monday, January 27th. Canaccord Genuity Group decreased their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a report on Monday, November 18th. Royal Bank of Canada initiated coverage on shares of GH Research in a report on Friday, March 7th. They set an "outperform" rating and a $31.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on shares of GH Research in a report on Thursday, February 13th. They set an "overweight" rating and a $14.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $30.86.

Remove Ads

GH Research Price Performance

GHRS opened at $11.35 on Thursday. The company has a market cap of $590.52 million, a price-to-earnings ratio of -14.37 and a beta of 0.94. The firm has a 50 day simple moving average of $11.03 and a 200 day simple moving average of $9.18. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50.

GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. As a group, analysts expect that GH Research will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GHRS. RA Capital Management L.P. boosted its holdings in shares of GH Research by 1.3% in the third quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company's stock valued at $44,734,000 after buying an additional 85,000 shares during the period. Geode Capital Management LLC lifted its position in shares of GH Research by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after purchasing an additional 3,092 shares in the last quarter. Diadema Partners LP bought a new stake in shares of GH Research in the fourth quarter worth $711,000. Lynx1 Capital Management LP lifted its position in shares of GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.